Home » USA Broker Ratings » Regeneron Pharmaceuticals, Inc. – Consenus Indicates Potential 38.5% Upside

Regeneron Pharmaceuticals, Inc. – Consenus Indicates Potential 38.5% Upside

Regeneron Pharmaceuticals, Inc. found using ticker (REGN) have now 18 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 496 and 325 with the average target price sitting at 386.33. Now with the previous closing price of 279 this now indicates there is a potential upside of 38.5%. The 50 day moving average now sits at 297.07 while the 200 day moving average is 335.29. The market cap for the company is $30,954m. Visit the company website at: http://www.regeneron.com

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi, Bayer, Teva, Mitsubishi Tanabe Pharma, Alnylam Pharmaceuticals, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.